The rationale to explain why ACC displays resistance to immunotherapy could be linked to the above-mentioned molecular alterations highly prevalent in ACC, namely, mutations in TP53 and CTNNB genes [17, 32, 33]. The gene discussed is TP53; the disease is adrenal cortex carcinoma.